A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

NCT06690671 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Non-Small Cell

Interventions

DRUG: Golidocitinib in combination with anti-PD-1

Sponsor

Shanghai Chest Hospital